Cholera– Pipeline Review, 2019

Cholera is an acute epidemic infectious disease. It can be characterized by watery diarrhoea, severe dehydration and extreme loss of fluids and electrolytes. Cholera is caused due to bacterium Vibrio cholera. According to an article published in NCBI, researchers has estimated that 1.3 million to 4.0 million cases of cholera are reported each year in endemic countries.

Current treatment for cholera includes administration of oral rehydration solution (ORS) and antibiotics. The main aim of current treatments is restoration of fluids, and reduction of fluid loss. Zinc is used for treatment of cholera in pediatric patients. World Health Organization has approved Dukoral, Shanchol, and Euvichol-Plus for the treatment of cholera.

Research Institutes and pharmaceutical companies have focussed on studying and developing new methods for the treatment of cholera. For instance; HL-OCV, which is being studied by the International Centre for Diarrhoeal Disease Research, Bangladesh in collaboration with MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd., is currently in phase-1 clinical trials for the study safety and immunogenicity outcome of the HL-OCV compared to Shanchol vaccine.

Currently, more than 50% of the pipeline candidates for cholera are in phase 2 and phase 3 stage. Majority of the studies have been sponsored by research institutes.

Report Description

The report on ‘Cholera– Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for cholera. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for cholera.

The report on ‘Cholera – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target


• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration


• Overview of dormant and discontinued pipeline products


• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products


• Overview of the latest developments; news articles, press releases and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.


• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for cholera


• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players


• Identify the focus of leading players in relation to R&D for cholera


• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business


• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary